NASDAQ:ACRS Aclaris Therapeutics - ACRS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.09 -0.24 (-2.88%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.04▼$8.7350-Day Range$7.07▼$17.4852-Week Range$5.77▼$18.96Volume693,032 shsAverage Volume1.75 million shsMarket Capitalization$539.52 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aclaris Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside295.6% Upside$32.00 Price TargetShort InterestBearish8.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingSelling Shares$994,615 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.73) to ($1.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.85 out of 5 starsMedical Sector728th out of 996 stocksPharmaceutical Preparations Industry353rd out of 484 stocks 3.5 Analyst's Opinion Consensus RatingAclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, Aclaris Therapeutics has a forecasted upside of 295.6% from its current price of $8.09.Amount of Analyst CoverageAclaris Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.12% of the float of Aclaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Aclaris Therapeutics has recently increased by 26.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRS. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Aclaris Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 15 people have searched for ACRS on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows6 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have sold 1,876.97% more of their company's stock than they have bought. Specifically, they have bought $50,310.00 in company stock and sold $994,615.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions95.33% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($1.73) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aclaris Therapeutics (NASDAQ:ACRS) StockAclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.Read More Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Stock News HeadlinesApril 1, 2023 | reuters.comACRS.OMarch 26, 2023 | americanbankingnews.comHead to Head Analysis: Albireo Pharma (NASDAQ:ALBO) and Aclaris Therapeutics (NASDAQ:ACRS)April 2, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 7, 2023 | markets.businessinsider.comAnalyst Ratings for Aclaris TherapeuticsMarch 6, 2023 | msn.comAclaris Plummets after Zunsemetinib Data DisappointsMarch 6, 2023 | marketwatch.comAclaris Therapeutics Shares Slide to Two-Year Lows on Study Failure >ACRSMarch 6, 2023 | reuters.comAclaris drug fails to treat skin disorder in mid-stage studyMarch 6, 2023 | marketwatch.comAclaris Shares Slide After Zunsemetinib Fails in Hidradenitis Suppurativa Study >ACRSApril 2, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 6, 2023 | reuters.comAclaris Therapeutics' drug fails in mid-stage study for skin disorderMarch 6, 2023 | msn.comAclaris stock falls ~35% as zunsemetinib fails mid-stage study in skin disorderMarch 6, 2023 | finance.yahoo.comAclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis SuppurativaFebruary 27, 2023 | msn.comAclaris Therapeutics's Return On Capital Employed InsightsFebruary 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Genmab (GMAB)February 23, 2023 | finance.yahoo.comAclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue EstimatesFebruary 9, 2023 | finance.yahoo.comAclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma ConferenceJanuary 24, 2023 | seekingalpha.comACRS Aclaris Therapeutics, Inc.January 14, 2023 | seekingalpha.comAclaris Therapeutics (ACRS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowJanuary 6, 2023 | finance.yahoo.comAclaris Therapeutics Provides 2023 OutlookDecember 2, 2022 | bizjournals.comLab Notes: Context identifies lead cancer drug candidate; Aclaris inks licensing deal worth up to $96MDecember 2, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)November 29, 2022 | markets.businessinsider.comAclaris Therapeutics, Pediatrix Therapeutics Ink License Deal For ATI-1777 In Greater ChinaNovember 29, 2022 | finance.yahoo.comAclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater ChinaNovember 27, 2022 | finance.yahoo.comLab Notes: Biotech firm bioMerieux unveils new product for detecting spoiled wineNovember 23, 2022 | marketwatch.comAclaris Therapeutics Names New CEO, CFO in Leadership ShuffleNovember 22, 2022 | finance.yahoo.comAclaris Therapeutics Announces Key Leadership TransitionsNovember 16, 2022 | finance.yahoo.comAclaris Therapeutics Looks Promising on the ChartsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Company Calendar Last Earnings2/23/2023Today4/02/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRS CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees72Year Founded2012Price Target and Rating Average Stock Price Forecast$32.00 High Stock Price Forecast$43.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+295.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,910,000.00 Net Margins-292.11% Pretax Margin-292.11% Return on Equity-41.71% Return on Assets-33.86% Debt Debt-to-Equity RatioN/A Current Ratio10.56 Quick Ratio10.55 Sales & Book Value Annual Sales$29.75 million Price / Sales18.14 Cash FlowN/A Price / Cash FlowN/A Book Value$2.96 per share Price / Book2.73Miscellaneous Outstanding Shares66,690,000Free Float62,225,000Market Cap$539.52 million OptionableOptionable Beta0.60 Social Links Key ExecutivesDouglas J. ManionPresident, Chief Executive Officer & DirectorKevin BalthaserChief Financial OfficerGail CawkwellChief Medical OfficerJoseph B. MonahanChief Scientific OfficerJames LoeropChief Business OfficerKey CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLMorphoSysNASDAQ:MORZymeworksNYSE:ZYMEAldeyra TherapeuticsNASDAQ:ALDXProcaps GroupNASDAQ:PROCView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 2,628 shares on 3/23/2023Ownership: 0.051%Douglas J ManionBought 6,500 shares on 3/9/2023Total: $50,310.00 ($7.74/share)Neal WalkerSold 29,000 sharesTotal: $358,730.00 ($12.37/share)Joseph MonahanSold 14,800 sharesTotal: $183,076.00 ($12.37/share)Kevin BalthaserSold 1,000 sharesTotal: $12,290.00 ($12.29/share)View All Insider TransactionsView All Institutional Transactions ACRS Stock - Frequently Asked Questions Should I buy or sell Aclaris Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRS shares. View ACRS analyst ratings or view top-rated stocks. What is Aclaris Therapeutics' stock price forecast for 2023? 7 analysts have issued 1-year price objectives for Aclaris Therapeutics' shares. Their ACRS share price forecasts range from $21.00 to $43.00. On average, they predict the company's share price to reach $32.00 in the next year. This suggests a possible upside of 295.6% from the stock's current price. View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts. How have ACRS shares performed in 2023? Aclaris Therapeutics' stock was trading at $15.75 at the beginning of the year. Since then, ACRS stock has decreased by 48.6% and is now trading at $8.09. View the best growth stocks for 2023 here. When is Aclaris Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our ACRS earnings forecast. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.03. The biotechnology company earned $7.80 million during the quarter, compared to analysts' expectations of $1.99 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 41.71% and a negative net margin of 292.11%. The company's revenue was up 420.0% on a year-over-year basis. During the same period last year, the firm earned ($0.37) EPS. What ETFs hold Aclaris Therapeutics' stock? ETFs with the largest weight of Aclaris Therapeutics (NASDAQ:ACRS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What is Neal Walker's approval rating as Aclaris Therapeutics' CEO? 1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX). What is Aclaris Therapeutics' stock symbol? Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS." How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aclaris Therapeutics' stock price today? One share of ACRS stock can currently be purchased for approximately $8.09. How much money does Aclaris Therapeutics make? Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $539.52 million and generates $29.75 million in revenue each year. The biotechnology company earns $-86,910,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. How can I contact Aclaris Therapeutics? Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344. This page (NASDAQ:ACRS) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.